Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study

Levels of IgG and IgM autoantibodies (AA) to malondialdehyde (MDA)-LDL and apoB-immune complexes (ICs) were measured in 748 cases and 1,723 controls in the EPIC-Norfolk cohort and their association to coronary artery disease (CAD) events determined. We evaluated whether AA and IC modify CAD risk associated with secretory phospholipase A2 (sPLA2) type IIA mass and activity, lipoprotein-associated PLA2 activity, lipoprotein (a) [Lp(a)], oxidized phospholipids on apoB-100 (OxPL/apoB), myeloperoxidase, and high sensitivity C-reactive protein. IgG ICs were higher in cases versus controls (P = 0.02). Elevated levels of IgM AA and IC were inversely associated with Framingham Risk Score and number of metabolic syndrome criteria (p range 0.02–0.001). In regression analyses adjusted for age, smoking, diabetes, LDL-cholesterol, HDL-cholesterol, and systolic blood pressure, the highest tertiles of IgG and IgM AA and IC were not associated with higher risk of CAD events compared with the lowest tertiles. However, elevated levels of IgM IC reduced the risk of Lp(a) (P = 0.006) and elevated IgG MDA-LDL potentiated the risk of sPLA2 mass (P = 0.018). This epidemiological cohort of initially healthy subjects shows that IgG and IgM AA and IC are not independent predictors of CAD events but may modify CAD risk associated with elevated levels of oxidative biomarkers.

[1]  D. Steinberg,et al.  Oxidized low-density lipoprotein and atherosclerosis. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[2]  G. Lambeau,et al.  Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers , 2010, Circulation.

[3]  K. Moore,et al.  Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. , 2010, Cell metabolism.

[4]  P. Talmud,et al.  Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. , 2010, Journal of the American College of Cardiology.

[5]  M. Lopes-Virella,et al.  Clinical significance of the humoral immune response to modified LDL. , 2010, Clinical immunology.

[6]  J. Frostegård.  Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. , 2010, Clinical immunology.

[7]  H. Brenner,et al.  Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. , 2009, European heart journal.

[8]  J. Boyle,et al.  Immunoglobulin M Is Required for Protection Against Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice , 2009, Circulation.

[9]  P. Libby,et al.  Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Choleste , 2009, Journal of the American College of Cardiology.

[10]  F. Bäckhed,et al.  Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. , 2009, The Journal of clinical investigation.

[11]  J. Witztum,et al.  The role of innate immunity in atherogenesis11 Guest editor for this article was Linda Curtiss, the Scripps Research Institute. Published, JLR Papers in Press, December 22, 2008. , 2009, Journal of Lipid Research.

[12]  A. DeMaria,et al.  Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. , 2008, Journal of the American College of Cardiology.

[13]  Christina Lindahl,et al.  High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. , 2008, Journal of the American College of Cardiology.

[14]  S. Tsimikas,et al.  Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. , 2007, Minerva cardioangiologica.

[15]  S. Kaveri,et al.  Phosphorylcholine-targeting immunization reduces atherosclerosis. , 2007, Journal of the American College of Cardiology.

[16]  R. Luben,et al.  Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. , 2007, Journal of the American College of Cardiology.

[17]  R. Luben,et al.  Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[18]  E. Brilakis,et al.  Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events Published, JLR Papers in Press, November 8, 2006. , 2007, Journal of Lipid Research.

[19]  P. Shah,et al.  Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice , 2007, Autoimmunity.

[20]  S. Tsimikas.  Oxidative biomarkers in the diagnosis and prognosis of cardiovascular disease. , 2006, The American journal of cardiology.

[21]  R. Peters,et al.  C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. , 2006, Atherosclerosis.

[22]  Qingbo Xu,et al.  Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study. , 2006, Journal of the American College of Cardiology.

[23]  F. Kronenberg,et al.  Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. , 2006, Journal of the American College of Cardiology.

[24]  P. Ridker,et al.  Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. , 2006, Journal of the American College of Cardiology.

[25]  N. Day,et al.  Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Baars,et al.  Therapy with interleukin-2 induces the systemic release of phospholipase-A2 , 1995, Cancer Immunology, Immunotherapy.

[27]  J. Witztum,et al.  Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. , 2004, Diabetes.

[28]  W. Sasiela,et al.  High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial , 2004, Circulation.

[29]  B. Strauss,et al.  Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein , 2004, Circulation.

[30]  F. Cambien,et al.  Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. , 2003, Journal of lipid research.

[31]  Joseph Juliano,et al.  Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[32]  J. Witztum,et al.  Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[33]  L. Berglund,et al.  Circulating Immune Complexes in 50-Year-Old Men as a Strong and Independent Risk Factor for Myocardial Infarction , 2000, Circulation.

[34]  M. Uusitupa,et al.  Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[35]  E. Dennis,et al.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. , 1999, The Journal of clinical investigation.

[36]  U. de Faire,et al.  Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. , 1999, Hypertension.

[37]  L. Berglund,et al.  Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  S. Young,et al.  Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[39]  L. Tenkanen,et al.  Antibody against oxidized low-density lipoprotein predicting myocardial infarction. , 1994, Archives of internal medicine.

[40]  V. Ord,et al.  ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[41]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.